Stock listing

Shenzhen:300199 Hybio Pharmaceutical Co., Ltd. (翰宇药业) 股价

Follow Hybio Pharmaceutical Co., Ltd. into a list and get an email when it puts out news.

Share price · SZSE:300199

¥19.59 CNY -1.90 (-8.8%)

Close on Nov 20, 2026

Past year +5.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
¥19.59 – ¥20.68 CNYNov 20, 2026
Volume
27.32M sharesNov 20, 2026
Market cap
¥17.30B CNYAt the close on Nov 20, 2026 · price × 883.2M shares outstanding
52-week range
¥16.23 – ¥27.70 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
¥1.06B CNYMedian day 39.02M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Hybio Pharmaceutical Co., Ltd. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SZSE:300199 · CNY, adjusted for splits

DayCloseChange%OpenHighLowVolume
¥19.59-1.90-8.8%¥20.60¥20.68¥19.5927,316,237
¥21.49-0.71-3.2%¥22.36¥22.43¥21.0030,200,110
¥22.20+0.17+0.8%¥21.86¥22.56¥21.7025,079,498
¥22.03-0.76-3.3%¥22.42¥22.78¥21.8927,147,689
¥22.79-0.26-1.1%¥23.15¥23.85¥22.7038,240,511
¥23.05-0.47-2.0%¥23.40¥23.91¥23.0332,142,235
¥23.52-0.08-0.3%¥23.42¥23.62¥22.9231,487,348
¥23.60+0.05+0.2%¥24.01¥24.17¥23.3028,630,338
¥23.55-0.59-2.4%¥24.60¥24.83¥23.5434,239,730
¥24.14-0.73-2.9%¥24.10¥24.85¥23.9750,425,233
¥24.87+2.16+9.5%¥22.71¥25.27¥22.7168,921,862
¥22.71+1.50+7.1%¥21.09¥22.88¥21.0245,806,354
¥21.21-0.88-4.0%¥21.87¥22.20¥21.2032,039,060
¥22.09+0.23+1.1%¥21.74¥22.35¥21.3528,573,650
¥21.86-0.45-2.0%¥22.52¥23.25¥21.0240,645,702
¥22.31-0.85-3.7%¥22.99¥23.20¥22.2333,171,321
¥23.16-0.04-0.2%¥23.20¥23.68¥22.8734,957,035
¥23.20-1.24-5.1%¥24.95¥25.15¥23.2049,047,688
¥24.44-1.36-5.3%¥25.35¥25.48¥24.3945,912,124
¥25.80+1.16+4.7%¥24.34¥25.96¥24.0256,935,914
¥24.64-2.07-7.7%¥26.50¥26.75¥24.6166,329,671
¥26.71+0.21+0.8%¥26.83¥27.70¥26.6269,938,638
¥26.50+0.20+0.8%¥25.83¥26.78¥25.5658,709,109
¥26.30+1.37+5.5%¥24.85¥26.50¥24.4878,983,047
¥24.93+0.38+1.5%¥25.01¥26.37¥24.6470,831,043
¥24.55-0.33-1.3%¥24.56¥25.67¥24.4362,294,129
¥24.88-0.67-2.6%¥24.99¥25.69¥24.6363,345,035
¥25.55+0.66+2.7%¥25.18¥26.38¥24.98103,980,414
¥24.89+1.18+5.0%¥23.60¥25.15¥23.0171,768,109
¥23.71-0.04-0.2%¥23.52¥23.84¥22.7441,550,457
¥23.75-0.17-0.7%¥24.16¥24.29¥23.3653,998,613
¥23.92+1.13+5.0%¥22.70¥24.93¥22.7077,790,086
¥22.79+0.39+1.7%¥22.28¥23.04¥22.0628,227,367
¥22.40-0.90-3.9%¥23.13¥23.42¥22.3134,804,828
¥23.30-0.99-4.1%¥24.15¥24.25¥23.2343,955,848
¥24.29+0.44+1.8%¥24.10¥24.44¥23.7049,657,566
¥23.85+0.26+1.1%¥23.26¥24.18¥22.9053,689,184
¥23.59+0.09+0.4%¥23.50¥24.09¥23.3347,095,832
¥23.50-0.15-0.6%¥23.87¥24.19¥23.3239,092,480
¥23.65+0.12+0.5%¥23.40¥24.19¥23.3235,203,266
¥23.53-0.06-0.3%¥23.59¥23.75¥23.0334,157,801
¥23.59+0.08+0.3%¥23.55¥23.94¥23.1629,548,527
¥23.51+0.74+3.2%¥22.70¥23.63¥22.5236,898,094
¥22.77-0.48-2.1%¥23.25¥23.27¥22.2630,902,922
¥23.25+0.09+0.4%¥23.12¥23.56¥22.6530,731,164
¥23.16+0.28+1.2%¥22.59¥23.78¥22.4939,710,660
¥22.88-0.55-2.3%¥23.51¥23.58¥22.8133,685,605
¥23.43+0.61+2.7%¥22.80¥23.55¥22.6538,947,895
¥22.82-0.02-0.1%¥23.10¥23.27¥22.6037,394,715
¥22.84-0.010.0%¥22.97¥23.30¥22.5131,054,096
¥22.85-0.10-0.4%¥22.95¥23.00¥22.3924,224,355
¥22.95-0.010.0%¥23.00¥23.08¥22.6325,121,035
¥22.96-0.49-2.1%¥23.08¥24.04¥22.7738,742,910
¥23.45+0.11+0.5%¥23.33¥24.02¥23.0937,388,695
¥23.34+0.67+3.0%¥22.71¥23.45¥22.4133,817,426
¥22.67-0.81-3.4%¥23.32¥23.50¥22.5740,592,578
¥23.48+1.31+5.9%¥22.09¥23.70¥21.7158,949,246
¥22.17-0.93-4.0%¥23.11¥23.21¥21.7047,457,625
¥23.10-1.00-4.1%¥24.00¥24.08¥22.9550,297,199
¥24.10+0.30+1.3%¥24.51¥25.13¥23.8862,392,488

Splits

3 splits since 2012 · SZSE:300199 · every price before a split is adjusted for it

DayRatioWhat
2-for-1Split
2-for-1Split
2-for-1Split
Ticker
Shenzhen:300199
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Shenzhen
Currency
CNY

What changed lately

Latest news

All Hybio Pharmaceutical Co., Ltd. news

Hybio Pharmaceutical Co., Ltd. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
3 in the last 12 months · 4 in all · newest Jul 6, 2026 · oldest 2025

Valuation

P/E 43.1× against a median of 18.5×: 9th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
¥18.03B CNY
P/E
43.1×
EV/sales
11.8×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
16.1×
Gross margin
62.9%
Operating margin
35.2%
Net margin
26.3%
Debt to equity
0.9×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Hybio Pharmaceutical Co., Ltd. Class A · SZSE:300199US$2.60BUS$2.71B43.1×11.8×n/a16.1×26.3%0.9×n/a
China Medical System Holdings Ltd. · HKEX:867US$2.87BUS$2.13B12.8×1.7×7.7×1.1×18.1%0.1×n/a
Joincare Pharmaceutical Group Industry Co., Ltd. Class A · SSE:600380US$2.80BUS$1.16B16.5×0.6×n/a1.3×8.4%0.1×n/a
Livzon Pharmaceutical Group, Inc. Class A · SZSE:000513US$2.72BUS$1.65B11.7×1.1×n/a1.4×15.2%0.0×n/a
Bavarian Nordic A/S · OMXCOP:BAVAUS$2.70BUS$2.38B20.5×2.6×8.6×1.4×14.2%0.0×n/a
Betta Pharmaceuticals Co., Ltd. Class A · SZSE:300558US$2.64BUS$2.72B66.1×4.8×n/a2.7×7.0%0.2×n/a
Hanmi Science Co., Ltd · KRX:008930US$2.60BUS$2.53B23.2×2.5×57.2×3.3×10.8%0.0×n/a
Hypera S.A. · BMFBOVESPA:HYPE3US$2.59BUS$3.57B8.5×2.3×7.4×1.0×20.1%0.5×n/a
Kangmei Pharmaceutical Co., Ltd Class A · SSE:600518US$2.57BUS$2.37B189×3.3×n/a2.3×1.9%0.0×n/a
Granules India Limited · NSE:GRANULESUS$2.42BUS$2.32B31.4×3.6×16.1×3.4×12.1%0.2×n/a
Prestige Consumer Healthcare Inc. · NYSE:PBHUS$2.35BUS$4.39B15.2×3.8×13.4×1.2×13.3%1.1×0.34
Median of the othersUS$2.62BUS$2.37B18.5×2.5×11.0×1.4×12.7%0.1×0.34

Events

QuarterResultsShare move
Q3 2025Oct 29, 2025−6.3%
Q2 2025Aug 22, 2025−3.3%
Q1 2025Apr 25, 2025 · Before open−0.3%
Q3 2024Oct 29, 2024 · Before open−2.3%
Q2 2024Aug 24, 2024+1.3%
Q1 2024Apr 26, 2024 · After close+0.6%
Q3 2023Oct 30, 2023−2.2%
Q2 2023Aug 15, 2023−5.1%
Q1 2023Apr 27, 2023+7.4%
Q3 2022Oct 29, 2022+4.2%
All 15 quarters
QuarterResultsShare move
Q2 2022Aug 27, 2022+0.5%
Q1 2022Apr 28, 2022 · Before open+1.1%
Quarter to Sep 30, 2021Oct 29, 2021+7.2%
Quarter to Jun 30, 2021Aug 28, 2021−2.1%
Quarter to Mar 31, 2021Apr 28, 2021 · Before open+0.6%

Open Events

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue966.4M590.2M431.4M704.3M736.0M721.7M614.2M1.26B1.25B855.0M
Cost of revenue402.4M281.5M260.4M194.8M271.9M153.5M133.9M184.3M197.0M169.8M
Gross profit564.0M308.7M171.0M509.5M464.1M568.2M480.3M1.08B1.05B685.2M
Research and development126.9M88.0M161.5M158.7M105.7M143.9M180.3M94.9M89.4M60.4M
Selling, general and administrative117.4M119.5M121.1M101.7M100.3M69.7M162.2M151.2M113.5M129.6M
Operating income218.5M-161.4M-507.5M-370.8M39.1M-574.4M-905.3M-320.3M354.4M277.9M
Depreciation and amortization132.7M148.3M154.9M144.5M135.8M108.7M105.5M100.9M100.4M90.9M
EBITDA351.3M-13.1M-352.6M-226.3M174.9M-465.7M-799.8M-219.5M454.8M368.8M
Interest expense98.0M117.9M125.8M109.7M99.7M65.3M94.5M48.4M25.9M40.7M
Income before tax64.2M-162.4M-511.1M-372.8M33.7M-588.2M-891.3M-333.7M350.5M309.2M
Income tax17.7M4.34M-265.0K5.24M21.1M-6.53M7.05M20.8M17.3M
Net income36.6M-173.7M-513.9M-370.6M30.8M-609.4M-884.8M-340.8M329.7M291.9M
Earnings per share, basic0.04-0.20-0.58-0.420.03-0.69-1.00-0.370.350.33

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents100.7M94.9M344.0M106.3M138.9M451.6M820.8M1.56B1.27B880.5M
Short-term investments1.23M1.11M160.6M477.7M
Receivables121.6M104.9M152.1M329.9M334.5M355.1M847.3M1.25B1.17B813.8M
Inventory261.4M238.6M152.6M190.0M157.1M186.8M152.0M161.6M142.8M136.6M
Current assets523.6M463.0M683.6M812.3M1.16B1.05B1.89B3.02B2.60B1.84B
Property, plant and equipment1.94B1.99B1.98B1.79B1.33B1.06B965.1M
Goodwill191.1K343.6M872.4M898.6M
Total assets3.15B3.01B3.28B3.61B3.91B4.04B4.72B5.66B5.30B4.46B
Accounts payable262.0M218.3M108.5M129.1M90.7M125.5M130.1M74.4M49.1M53.1M
Current liabilities1.78B1.42B1.42B1.15B743.8M1.11B1.14B831.9M865.0M330.9M
Long-term debt623.4M861.1M938.6M1.02B1.37B1.14B1.27B1.35B458.5M421.2M
Total debt1.50B1.56B1.34B1.71B1.74B1.91B1.76B774.8M417.7M
Total liabilities2.52B2.41B2.49B2.31B2.26B2.36B2.49B2.27B1.41B852.4M
Shareholders' equity614.0M578.6M758.8M1.27B1.58B1.64B2.23B3.39B3.88B3.60B
Shares outstanding883.2M868.3M886.0M883.2M883.2M883.2M883.2M921.0M942.1M884.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations233.9M164.7M-3.54M15.8M156.8M48.0M104.6M47.0M228.6M296.4M
Capital spending-234.4M-115.8M-81.8M-189.8M-199.0M-243.7M-570.2M-365.6M-221.1M-116.1M
Free cash flow-449.8K48.9M-85.3M-174.0M-42.2M-195.7M-465.5M-318.6M-7.39M180.4M
Cash from investing-70.0M147.7M51.7M-178.4M-258.5M-596.0M-419.9M-223.5M-131.0M
Cash from financing-345.5M95.8M-71.1M-253.7M-71.7M-425.2M654.6M393.2M524.4M
Dividends paid-94.8M-111.7M-117.9M-114.8M-115.6M-105.0M-114.6M-252.8M-128.3M-63.1M
Share buybacks-413.2M-105.9M
Change in cash-15.3M-247.4M240.9M-1.51M-276.8M-280.2M-906.7M295.8M387.9M694.8M

Open Financials

Cap table

Built by 6ix from Hybio Pharmaceutical Co., Ltd. Class A’s releases

Common shares
883,241,336
Fully diluted
883,241,336

Fully diluted

LineShares
Common shares883,241,336

Share count over time

CountShares
Nov 22, 2026883,241,336

Open Cap table

Shareholders

HolderSharesValueChangeAs of
Vanguard Total International Stock Index Fund885KUS$2.76MNo changeJul 31, 2026
Vanguard Emerging Markets Stock Index Fund803KUS$2.51MNo changeJul 31, 2026
Vanguard Ftse All-World Ex-Us Small-Cap Index Fund240KUS$750KNo changeJul 31, 2026
Dimensional Emerging Core Equity Market ETF60,400US$189K+18,000Jul 31, 2026
The Emerging Markets Series52,300US$163KNewJul 31, 2026
Vanguard Total World Stock Index Fund43,100US$135KNo changeJul 31, 2026
Emerging Markets Core Equity 2 Portfolio27,900US$87,116No changeJul 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF8,800US$27,494NewJul 31, 2026
Dimensional Emerging Markets High Profitability ETF400US$1,250NewJul 31, 2026

Open Shareholders

Log in to ask 6ix AI your own questions about Hybio Pharmaceutical Co., Ltd.